ProfessionalHybridDiscontinued

Certificate in Psychedelic-Assisted Therapies

The course is based on the CIIS program, adapted for the Australian context, and with input from MAPS, USONA, and others. It teaches therapists the research, therapy setting, risks, and therapeutic models for working with psychedelics.

Provider

Mind Medicine Australia

English

Schedule

Enrollment

$9,950

Decision Summary

Best fit
Medical, Mental Health and Allied Health Professionals in Australia
Format
Hybrid
Time commitment
Estimated 121 hours
Credential signal
CME
Delivery
Online + Australia

Course Overview

The Certificate in Psychedelic-Assisted Therapies (CPAT) by Mind Medicine Australia (MMA) is designed to meet the growing demand for trained therapists to provide regulatory-approved and research-backed psychedelic-assisted therapies for mental ill-health treatment in Australia. The course also prepares clinicians to work in research trials as they expand within the country.

Following world best practices, the CPAT is developed based on protocols from MAPS and the REBUS model by Imperial College London. The course aims to equip therapists with state change and stage change theory and technique, provide a theory of mind perspective, train therapists for future demands, help with the mental health crisis, contribute to changing attitudes and supporting legal changes, establish standards for safe and ethical practice, and bring together medical approaches with good psychotherapy standards and transpersonal aspects.

The CPAT program was developed through collaboration with experienced psychotherapists and incorporated live lectures, webcasts, self-study, and experiential workshops led by a skilled teaching team. The course respects the local context within Australia, making it the first program of its kind in the Southern Hemisphere.

Who is this for?

Medical, Mental Health and Allied Health Professionals in Australia

Prerequisites

The course has 4 assessment requirements:

About the Provider

Australian registered charity founded in 2019 that successfully campaigned for the Therapeutic Goods Administration (TGA) to reschedule psilocybin and MDMA in 2023 — making Australia the first country to formally approve these substances for clinical use. MMA trains clinicians through its Certificate in Psychedelic-Assisted Therapies (CPAT) program, funds clinical trials, and has supplied medicines and training to 100+ patients under the TGA Authorised Prescriber scheme.

Course FAQ

Who is this course for?

Medical, Mental Health and Allied Health Professionals in Australia

Are there prerequisites?

The course has 4 assessment requirements:

What is the format and time commitment?

Format: Hybrid.

How much does it cost?

The listed price is $9,950. Confirm the latest tuition, fees, and payment options with [object Object].

Does it offer a certificate or CE/CME credit?

The listing includes a certificate signal. Accreditation note: CME. Confirm credential eligibility directly with the provider before enrolling.

When does the next cohort start?

The listed next cohort date is 2026-06-01.

Is this course currently available?

The current listing status is Discontinued. Use the provider website for the latest enrollment status.

Related Courses

View all courses